SINGAPORE, Feb. 22, 2018 /PRNewswire/ — Mundipharma has expanded its partnership with Celltrion Healthcare to include the distribution and marketing of Truxima® (rituximab) in Colombia under licence. In February 2017 Mundipharma launched Truxima® in several European markets, where it was the first biosimilar monoclonal antibody (mAb) licensed for the treatment of cancer.[1]

It has been approved for use in all indications of the reference product Mabthera®[2], based on its preclinical, safety and efficacy data. In Europe, Truxima® is authorised for the treatment of diffuse large B cell Non-Hodgkin’s lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.[3]

Truxima® is intended to cost less than the reference product, which was the world’s top selling cancer drug in 2015, costing healthcare systems over US$7.1 billion worldwide.[4] Mundipharma believes that cost savings from using this biosimilar rituximab will enable access for patients in need of new innovative cancer therapies.[5]

"Mundipharma is constantly seeking opportunities to develop and commercialise sustainable and affordable medicines for new markets," said Raman Singh, CEO, Mundipharma.

"We are excited to expand our partnership with Celltrion Healthcare to include Truxima® in Colombia. As a core therapy for hematological malignancies, we see it as a good fit with our existing potfolio of products such as Difolta® and Zevalin®," he added. 

[1] EMA. Human Medicines Truxima

[2] Mabthera Summary of Product Characteristics. Available online at:

[3] European Medicines Agency. Summary of Product Characteristics Truxima. Available here

[4] Pharmaceutical Technology . The world’ s most sold cancer drugs in 2015. Available at:

[5] Laslop A. Biosimilar monoclonal antibodies — challenges and opportunities in Europe. GaBI Journal. 2013; 2: 110–111

About Truxima®

Truxima® is a biosimilar rituximab which demonstrates high comparability to the reference medicinal product. Truxima® reduces disease symptoms by specifically inhibiting the overactive growth and excessive spread of B cells. Truxima® is used for patients for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA).

® : Truxima is a registered trademark of Celltrion Healthcare
®: Mabthera is a registered trademark of F. Hoffmann La-Roche AG

About Celltrion Healthcare

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.

For more information, please visit:

About Mundipharma

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information, please visit:  

Logo –